Related Experiment Video
Updated: Aug 16, 2025

07:59
Murine Full-thickness Skin Transplantation
Published on: January 2, 2017
20.4K
Post-treatment course of acute lipodermatosclerosis
Kotaro Suehiro1, Noriyasu Morikage1, Takasuke Harada1
1Division of Vascular Surgery, Department of Surgery and Clinical Science, 38152Yamaguchi University Graduate School of Medicine, Japan.
Phlebology
|December 19, 2022
Summary
Acute lipodermatosclerosis (LDS) can progress to chronic LDS. Subcutaneous tissue changes in the acute phase may predict progression, suggesting long-term compression therapy may not alter the outcome.
Area of Science:
- Vascular Medicine
- Dermatology
- Clinical Research
Background:
- Lipodermatosclerosis (LDS) is a chronic inflammatory condition affecting subcutaneous fat, typically in the lower legs.
- Understanding the progression from acute to chronic LDS is crucial for effective management.
- The role of compression therapy in preventing chronic LDS progression remains unclear.
Approach:
- This study retrospectively analyzed 30 patients diagnosed with acute/subacute LDS between April 2015 and November 2021.
- Patients were followed for over a year after initial treatment with compression bandages.
- Treatment outcomes and post-treatment disease courses were reviewed to identify predictors of progression.
Key Points:
- Compression bandages effectively resolved acute-phase symptoms in all patients.
- Over half of the legs (56%) progressed to chronic LDS after discontinuing compression therapy.
- Legs that did not progress to chronic LDS showed significantly thicker subcutaneous tissue initially compared to those that did.
Conclusions:
- Initial subcutaneous tissue thickness may indicate risk for progression to chronic LDS.
- Subcutaneous tissue contraction, indicative of underlying panniculitis, may be present even in the acute phase.
- Long-term compression therapy might not significantly alter the prognosis for patients with acute LDS who are destined to develop chronic LDS.
Related Concept Videos
Atherosclerosis III: Management
19
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
19
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
747
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
747

